{
  "source": "PA-Notification-Enspryng.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1331-5\nProgram Prior Authorization/Notification\nMedications Enspryng™ (satralizumab-mwge)\nP&T Approval Date 10/2020, 10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nEnspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the\ntreatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-\naquaporin-4 (AQP4) antibody positive.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Enspryng will be approved based on all of the following criteria:\na. Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)\n-AND-\nb. Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies\n-AND-\nc. Patient is not receiving Enspryng in combination with any of the following:\n(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya\n(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]\n(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]\n(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]\n(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Enspryng will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Enspryng therapy\n-AND-\nb. Patient is not receiving Enspryng in combination with any of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya\n(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]\n(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]\n(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]\n(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal reg",
    "therapy [e.g., Actemra (tocilizumab)]\n(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity, Supply limits may be in place.\n4. References:\n1. Enspryng [package insert]. South San Francisco, CA: Genentech, Inc.; March 2022.\nProgram Prior Authorization/Notification – Enspryng (satralizumab-mwge)\nChange Control\n10/2020 New program.\n10/2021 Annual review with no changes to clinical criteria.\n10/2022 Annual review with no changes to clinical criteria. Added state\nmandate footnote. Updated reference.\n10/2023 Annual review. No changes.\n10/2024 Annual review. No changes to coverage criteria. Updated examples of\ncomplement inhibitors.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}